Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Recruiting

• Conditions: Sarcomatoid Carcinoma; Liver Cancer; Adjuvant Therapy

• Registration Number: NCT06950814
• Lead Sponsor: West China Hospital

Brief Summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study Start: 2025-04-05
• Study First Submitted: 2025-04-22
• Study First Submitted QC: 2025-04-22
• Last Update Submitted: 2025-04-22
• Study First Posted: 2025-04-30
• Last Update Posted: 2025-04-30
• Primary Completion: 2025-05-03
• Study Completion: 2025-05-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. patients who underwent liver resection
2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion Criteria

1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
2. patients diagnosed with other specific types of sarcomas;
3. patients with concurrent other malignancies during the course of PHSC;
4. patients who were lost to follow-up or lacked essential clinical data.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free survival	From December 2018 to May 2023	Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.

Secondary Outcome Measures

Name	Time	Method
Overall survival	From December 2018 to May 2023	Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.

Trial Locations

Locations (1)

West China Hospital; 🇨🇳 Chengdu, Sichuan, China